PARK CITY, Utah, Nov. 6, 2023 /PRNewswire/ -- BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient centric implantable Tibial NeuroModulation (iTNM) solution for ...

VALENCIA, Calif.--(BUSINESS WIRE)--Bioness, Inc. announced today that the first commercial procedure of StimRouter ™ Neuromodulation System has been performed under the company’s FDA clearance to ...

Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...

New data from the United States bolster the case for dementia prevention. At the same time, noninvasive stimulation procedures are still not being used to treat Alzheimer's disease (AD) in day-to-day ...

Medtech analysts at Needham & Co. surveyed 25 urologists that reported doing a median of 30 sacral neuromodulation procedures a year. While the survey implications weren't necessarily bad for Axonics, ...

DUBLIN--(BUSINESS WIRE)--The "United States Neurology Procedures Outlook to 2025 - Hydrocephalus Shunting Procedures, Neurovascular Thrombectomy Procedures, ICP Procedures and Others" report has been ...

BlueWind announced today that the FDA granted 510(k) clearance for its enhanced Revi implantable tibial neuromodulation (iTNM ...

The global neuromodulation devices market is poised to witness substantial growth, projected to expand at a CAGR of 9–11% over the next five years. This growth is primarily driven by the increasing ...